GSK to acquire full ownership of BENLYSTA, albiglutide and darapladib. Acquisition will be accretive to GSK core earnings in 2013. The transaction is: “well aligned with GSK’s long-term strategy of delivering sustainable growth, simplifying GSK’s business model, enhancing R&D returns and deploying capital with discipline."
